Dr. James H. Rubenstein, MD

Dr. Rubenstein practices at Advocate Radiation Oncology in Port Charlotte, Florida.

Dr. Rubenstein's NPI, 1194710384, was assigned on September 14, 2005. Dr. Rubenstein graduated from New York University School of Medicine in 1981. Dr. Rubenstein holds Florida license ME0055380.

Dr. Rubenstein's primary practice is Advocate Radiation Oncology, at 3080 Harbor Blvd, Port Charlotte, FL 33952 in Charlotte County. The practice phone is (941) 883-2199.

Dr. Rubenstein's primary practice is Advocate Radiation Oncology in Port Charlotte, Florida. Dr. Rubenstein is also affiliated with Lee Memorial Hospital. The medical group on file is Advocate Radiation Oncology. Dmand AI also links Dr. Rubenstein to 2 more hospitals, 2 group practices and clinics and 1 medical group, each named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Rubenstein practices, 5 sites in all. Vendor and product names are available with a free account.

Radiation oncology is Dr. Rubenstein's primary specialty in the NPI Registry, under taxonomy code 2085R0001X. Dr. Rubenstein is board certified in internal medicine by the American Board of Internal Medicine. Dmand AI has Dr. Rubenstein's licenses on file in 4 states: Florida, New York, New Jersey and Pennsylvania.

Dmand AI lists anal cancer radiation, bone cancer radiation, brain tumor radiation, breast cancer radiation, colorectal cancer radiation, head & neck cancer radiation, lung cancer radiation and prostate cancer radiation among the conditions Dr. Rubenstein treats.

CMS data shows 3,449 Medicare services from Dr. Rubenstein across 14 procedure codes in 2024, for 735 Medicare patients. Medicare paid $867,513 for them. Every service was in an office.

CMS counts 735 Medicare patients who saw Dr. Rubenstein in 2024. The largest group is 75 to 84, with 313 patients. 75% of them have high blood pressure, and 75% have high cholesterol. 5% are also on Medicaid. Their average risk score is 1.95, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Dr. Rubenstein's median patient age at 75, with 43% women.

In 2024, Dr. Rubenstein wrote 13 Medicare Part D claims. Every claim was for a generic drug. They cover 1 drug, with $273,465 in total drug cost.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 92 out of 100 for Dr. Rubenstein for performance year 2024, reported as part of a group. Dr. Rubenstein accepts Medicare assignment, so Medicare's approved amount is taken as full payment. CMS lists Dr. Rubenstein as offering telehealth.

Dmand AI links 13 papers to Dr. Rubenstein. The most frequent topics are Lung Neoplasms, Radiotherapy Dosage and Adenocarcinoma. Dr. Rubenstein has published most often in Int J Radiat Oncol Biol Phys. Dr. Rubenstein's most frequent co-authors are Daniel E. Dosoretz, MD, Michael J. Katin, MD and Thomas E. Teufel, MD.

CMS Open Payments shows 29 general payments to Dr. Rubenstein from 12 drug and device companies from 2018 to 2025. Food and beverage make up the largest share, 63% of the total. Siemens Medical Solutions USA, Inc. paid the most, $804.

Dmand AI lists 2 awards for Dr. Rubenstein, most recently CMS Stage 1 EHR in 2014.

Dr. Rubenstein graduated from New York University School of Medicine in 1981.

Dr. Rubenstein is in network with 17 carriers, including Aetna, Elevance and Excellus BlueCross BlueShield. Medicare plans come from the most carriers, 11. Check the plan with the practice before a visit.